Restatement of Previously Issued Condensed Consolidated Financial - Statements Of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	$ 9,410	$ 626	$ 20,741	$ 15,263
Depreciation and amortization			17,365	7,732
Amortization of deferred loan fees and line of credit fees			296	357
Amortization of label design fees			668	251
Litigation proceeds			0	(4,750)
Stock-based compensation expense			1,943	601
Provision for doubtful accounts			45	87
Impairment of inventory			0	3,302
Net unrealized gain on interest rate swap agreements	(13,841)	(5,589)	(17,870)	(8,212)
(Benefit) provision for deferred income tax			888	0
Loss (gain) on disposition of assets			508	(999)
Deferred gain on sale leaseback			(1,000)	(1,000)
Deferred rent			285	376
Accounts receivable			(21,261)	(1,001)
Related party receivables			0	(2,038)
Other receivables			376	(2,338)
Litigation receivable			0	4,750
Inventories			4,244	(8,964)
Prepaid expenses and other current assets			(2,232)	(5,829)
Other assets			(6,215)	1,688
Accounts payable			(8,106)	616
Accrued liabilities and other payables			5,421	16,073
Related party liabilities			0	3,698
Net cash (used in) provided by operating activities			(3,903)	19,661
Proceeds from disposition of assets			105	1,064
Purchases of property, plant, and equipment			(15,723)	(30,688)
Label design expenditures			(225)	(375)
Proceeds on related party notes receivable			0	756
Acquisition of businesses			(74,268)	0
Net cash used in investing activities			(90,111)	(29,243)
Repurchase of common stock			(2,833)	0
Principal payments on line of credit			(67,210)	(25,195)
Proceeds from line of credit			126,591	32,281
Outstanding checks in excess of cash			2,900	9,277
Principal payments on long-term debt			(13,178)	(15,234)
Proceeds from long-term debt			0	8,902
Principal payments on related party note			0	(489)
Deferred offering costs			0	(768)
Payments on acquisition payable			(226)	(486)
Net cash provided by financing activities			46,044	8,287
Net change in cash and restricted cash			(47,970)	(1,295)
Cash and restricted cash, beginning of period			123,679	1,751
Cash and restricted cash, end of period	75,709	$ 456	75,709	456
Interest			9,415	9,230
Income taxes			22	25
Contingent consideration in a business combination			8,460	0
Issuance of common stock in business combination			10,521
Accretion of redemption value of Series B redeemable cumulative stock			0	4,760
Accretion of redemption value of Series A redeemable stock			0	16,466
Offering costs			0	$ 535
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	2,707		14,038
Depreciation and amortization			17,365
Amortization of deferred loan fees and line of credit fees			296
Amortization of label design fees			668
Litigation proceeds			0
Stock-based compensation expense			1,943
Provision for doubtful accounts			45
Impairment of inventory			0
Net unrealized gain on interest rate swap agreements	(4,553)		(8,582)
(Benefit) provision for deferred income tax			888
Loss (gain) on disposition of assets			508
Deferred gain on sale leaseback			(1,000)
Deferred rent			285
Accounts receivable			(21,261)
Related party receivables			0
Other receivables			376
Litigation receivable			0
Inventories			4,244
Prepaid expenses and other current assets			(2,232)
Other assets			(6,215)
Accounts payable			(8,106)
Accrued liabilities and other payables			2,836
Related party liabilities			0
Net cash (used in) provided by operating activities			(3,903)
Proceeds from disposition of assets			105
Purchases of property, plant, and equipment			(15,723)
Label design expenditures			(225)
Proceeds on related party notes receivable			0
Acquisition of businesses			(74,268)
Net cash used in investing activities			(90,111)
Repurchase of common stock			(2,833)
Principal payments on line of credit			(67,210)
Proceeds from line of credit			126,591
Outstanding checks in excess of cash			2,900
Principal payments on long-term debt			(13,178)
Proceeds from long-term debt			0
Principal payments on related party note			0
Deferred offering costs			0
Payments on acquisition payable			(226)
Net cash provided by financing activities			46,044
Net change in cash and restricted cash			(47,970)
Cash and restricted cash, beginning of period			123,679
Cash and restricted cash, end of period	75,709		75,709
Interest			9,508
Income taxes			22
Contingent consideration in a business combination			8,460
Issuance of common stock in business combination			10,521
Accretion of redemption value of Series B redeemable cumulative stock			0
Accretion of redemption value of Series A redeemable stock			0
Offering costs			0
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	6,703		6,703
Net unrealized gain on interest rate swap agreements	$ (9,288)		(9,288)
Accrued liabilities and other payables			$ 2,585